论文部分内容阅读
目的评价两种三联疗法治疗幽门螺杆菌相关性胃病的疗效。方法136例幽门螺旋杆菌相关性胃病患者,其中消化性溃疡85例、慢性胃炎51例。消化性溃疡患者随机分为奥美拉唑组(42例)和枸橼酸铋钾组(43例),慢性胃炎患者随机分为奥美拉唑组(26例)和枸橼酸铋钾组(25例)。消化性溃疡患者给予三联治疗1周后分别予奥美拉唑和枸橼酸铋钾治疗6周、慢性胃炎给予三联治疗1周,疗程结束4周后复查胃镜,观察幽门螺杆菌(HP)根除率、溃疡愈合率。结果消化性溃疡患者奥美拉唑组与枸橼酸铋钾组HP根除率分别为95.2%和93.0%,差异无显著性(P>0.05);溃疡愈合率分别为95.2%和48.8%,差异有显著性(P<0.01);胃炎患者奥美拉唑组与枸橼酸铋钾组幽门螺旋杆菌根除率分别为92.3%和88.0%(P>0.05)。结论奥美拉唑方案治疗HP阳性的消化性溃疡疗效显著,枸橼酸铋钾方案治疗HP阳性胃炎疗效肯定而价廉。
Objective To evaluate the efficacy of two triple therapy in the treatment of Helicobacter pylori-associated gastropathy. Methods 136 patients with Helicobacter pylori-associated gastric diseases, including peptic ulcer in 85 cases, chronic gastritis in 51 cases. Patients with peptic ulcer were randomly divided into omeprazole group (42 cases) and bismuth potassium citrate group (43 cases). Patients with chronic gastritis were randomly divided into two groups: the omeprazole group (26 cases) and the bismuth potassium citrate group (25 cases). Patients with peptic ulcer were treated with omeprazole and bismuth potassium citrate for 6 weeks, triple therapy for chronic gastritis for 1 week, and gastroscopy for 4 weeks after the end of treatment, respectively, to observe the eradication of Helicobacter pylori (HP) Rate, ulcer healing rate. Results The eradication rates of HP in omeprazole group and bismuth potassium citrate group were 95.2% and 93.0%, respectively, with no significant difference (P> 0.05). The healing rates of ulcer were 95.2% and 48.8%, respectively (P <0.01). The H. pylori eradication rates in the omeprazole group and the bismuth potassium citrate group were 92.3% and 88.0%, respectively (P> 0.05). Conclusion The omeprazole regimen is effective in treating HP-positive peptic ulcer. The bismuth potassium citrate regimen is effective and inexpensive in the treatment of HP-positive gastritis.